Ccr2 is a therapeutic target for retinal degenerative disorders including AMD and RP because deletion of Ccl2, a cognate ligand for Ccr2, can rescue PCD in Mertk−/− mice [11] and deletion of Ccr2 ameliorated retinal degeneration in another model [23]. This evidence concerns the gene CCL2 and retinitis pigmentosa 1.